Zobrazeno 1 - 8
of 8
pro vyhledávání: '"J. M. Miyasaki"'
Autor:
D M, Simpson, J-M, Gracies, H K, Graham, J M, Miyasaki, M, Naumann, B, Russman, L L, Simpson, Y, So
Publikováno v:
Neurology. 70:1691-1698
Objective: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of adult and childhood spasticity.Methods: A literature search was performed including MEDLINE and Current Contents for therapeu
Autor:
W Thomas Thach, K Graham, Markus Naumann, William M. Landau, David M. Simpson, L Simpson, Bruce H. Dobkin, B Russman, Shirley A. Sahrmann, Yuen T. So, Mark Hallett, J-M Gracies, J. M. Miyasaki
Publikováno v:
Neurology. 73(9)
The Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (AAN) recommends that botulinum neurotoxin (BoNT) should be offered as an option for the treatment of spasticity.1 Despite offering a Level A rating of evide
Autor:
David M. Simpson, M. Naumann, J. M. Miyasaki, Christy L. Ludlow, Mark Hallett, Richard Dubinsky, A. Blitzer, Allison Brashear, Joseph Jankovic, Cynthia L. Comella, Yuen T. So, Barbara I. Karp
Publikováno v:
Neurology. 70(19)
Objective: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders.Methods: A literature search was performed including MEDLINE and Current Contents for therapeutic articles
Autor:
J. M. Miyasaki, K. Shannon, V. Voon, B. Ravina, G. Kleiner-Fisman, K. Anderson, L. M. Shulman, G. Gronseth, W. J. Weiner
Publikováno v:
Neurology. 66(7)
Objective: To make evidence-based treatment recommendations for patients with Parkinson disease (PD) with dementia, depression, and psychosis based on these questions: 1) What tools are effective to screen for depression, psychosis, and dementia in P
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 16(1)
Autor:
D. Aarsland, M. Emre, A. Lees, W. Poewe, C. Ballard, E. B. Montgomery, J. M. Miyasaki, G. Gronseth
Publikováno v:
Neurology. 68:80-81
Autor:
R. Inzelberg, P. Nisipeanu, E. Schechtman, J. M. Miyasaki, W. Martin, O. Suchowersky, W. Weiner, A. E. Lang
Publikováno v:
Neurology. 59:1292-1292
To the Editor: We have read with interest the practice parameter by Miyasaki et al.1 concerning the use of dopamine agonists (DA) in the treatment of patients with early Parkinson’s disease (PD). The authors stressed in this evidence-based review t
Publikováno v:
Neurology. 52:1717-1717
To the Editor: Factor et al.1 reported an interesting observation of delirium secondary to withdrawal of amantadine in demented patients with PD. Delirium and hallucinations cleared with reinstitution of amantadine. The etiology of this phenomenon is